4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of October 20, 2026, FDMT trades at $13.11 with a market cap of $678.95M and a P/E ratio of -4.80. FDMT moved +6.75% today. Year to date, FDMT is +78.96%; over the trailing twelve months it is +16.24%. Its 52-week range spans $2.24 to $16.93. Analyst consensus is strong buy with an average price target of $31.25. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for FDMT shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $13.11 |
| Market Cap | $678.95M |
| P/E Ratio | -4.80 |
| EPS | $-2.63 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.93 |
| 52-Week Low | $2.24 |
| Volume | 595.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $92.01M |
| Net Income | $-179.18M |
| Gross Margin | 0.00% |
10 analysts cover FDMT: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.25.